Whitefish, Mont. – September 25, 2026 -- STEMREGEN, a maker of science-backed stem cell supplements, has landed at No. 332 on the 2026 Inc. 5000 list after posting 1,017% revenue growth over three years, far outpacing the list's 130% median.

Company secures third straight Inc. 5000 ranking as growth trajectory accelerates

STEMREGEN previously ranked No. 265 in 2025 and No. 1,765 in 2024, marking three consecutive years on the annual list of America's fastest-growing private companies. The 2026 ranking measures revenue growth from 2022 through 2025.

Seoul – September 26, 2026 -- MAYPHARM has announced the upcoming launch of HYALMASS AQUATOX, a new aesthetic formulation combining five high-interest active ingredients into a single product for the global cosmeceutical market.

Pune, India – September 25, 2026 -- The global AI in Clinical Trials Market is set to more than triple from USD 2 billion in 2025 to USD 7.32 billion by 2034, expanding at a 15.5% compound annual growth rate, according to Maximize Market Research.

Pune – September 25, 2026 -- The global clinical trials market reached USD 58.19 billion in 2025 and is forecast to grow at a 6.13% compound annual rate through 2034, reaching USD 99.4 billion, according to Maximize Market Research.

Mississauga, ON – September 25, 2026 -- Kye Pharmaceuticals ranked No. 105 on Report on Business magazine's 2026 list of Canada's Top Growing Companies, posting three-year revenue growth of 264%.

Cambridge, Mass. – September 25, 2026 -- NeuroSense Therapeutics (NASDAQ: NRSN) cut operating expenses to $3.4 million in the first half of 2026, down from $4.7 million a year earlier, as the biotech pushes its ALS candidate PrimeC toward a Canadian regulatory filing targeted for December 2026.

Shanghai – September 25, 2026 -- IASO Biotechnology reported an 88.9% objective response rate for its dual-targeted CAR-T therapy RD140 in a first-in-human Phase 1 trial of nine heavily pretreated multiple myeloma and plasma cell leukemia patients, with the response rate reaching 100% in the higher-dose cohort.

Shanghai – September 25, 2026 -- A retrospective analysis of 102 multiple myeloma patients treated with IASO Bio's FUCASO CAR-T therapy found that patients maintaining sustained minimal residual disease (MRD) negativity showed a median CAR-T cell persistence of 463 days, compared with 272 days in patients who experienced MRD conversion — a gap of roughly 191 days. The data, drawn from the pivotal FUMANBA-1 registration study, were presented as a poster (Abstract No. PA-469) at the 2026 International Myeloma Society Annual Meeting.

San Mateo, Calif. – September 25, 2026 -- Kali Therapeutics has been named one of the 11 most promising private biotechnology companies in the 2026 Endpoints 11, a list curated annually by Endpoints News editors from hundreds of private candidates.

Emeryville, Calif. – September 25, 2026 -- Slingshot Biosciences has appointed Dr. Nimisha Srivastava as Chief Executive Officer, effective September 23, 2026, elevating the company's former Chief Operating Officer to its top leadership post.